AstraZeneca announced Wednesday that the results of the company’s TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly AZD7442) for the early outpatient treatment of mild-to-moderate COVID-19 have been published in The Lancet Respiratory Medicine. Results of the trial showed that Evusheld protected against progression to severe COVID-19 or death – from any cause – compared to placebo.